PMID- 37308914
OWN - NLM
STAT- MEDLINE
DCOM- 20230614
LR  - 20230615
IS  - 1748-717X (Electronic)
IS  - 1748-717X (Linking)
VI  - 18
IP  - 1
DP  - 2023 Jun 12
TI  - Lenvatinib with or without stereotactic body radiotherapy for hepatocellular 
      carcinoma with portal vein tumor thrombosis: a retrospective study.
PG  - 101
LID - 10.1186/s13014-023-02270-z [doi]
LID - 101
AB  - BACKGROUND AND OBJECTIVES: Patients with hepatocellular carcinoma (HCC) involving 
      portal vein tumor thrombosis (PVTT) are presently lacking effective treatment 
      options. We aimed to compare the efficacy and safety of lenvatinib with or 
      without SBRT for HCC with PVTT. MATERIALS AND METHODS: This retrospective 
      analysis included 37 patients treated with lenvatinib in combination with SBRT 
      and 77 patients treated with lenvatinib alone from August 2018 to August 2021. 
      Overall survival (OS), progression-free survival (PFS), intrahepatic PFS (IHPFS) 
      and objective remission rate (ORR) were compared between the two groups, while 
      adverse events (AEs) was analyzed between the two groups to assess safety 
      profiles. RESULTS: Median OS, PFS and IHPFS were significantly prolonged in the 
      combination treatment group compared with the single treatment group (median OS, 
      19.3 vs. 11.2 months, p < 0.001; median PFS: 10.3 vs. 5.3 months, p < 0.001; 
      median IHPFS, 10.7 vs. 5.3 months, p < 0.001). Moreover, a higher ORR (56.8% vs. 
      20.8%, P < 0.001) were observed in the lenvatinib combined with SBRT group. In 
      subgroup analyses of Vp1-2 and Vp3-4 group, median OS, PFS and IHPFS were also 
      significantly longer in the lenvatinib combined with SBRT group than those in the 
      lenvatinib alone group. AEs in the combined therapy group were mostly manageable 
      and the incidence was not statistically significant compared to the monotherapy 
      group. CONCLUSION: Lenvatinib plus SBRT had a significantly better survival 
      benefit than lenvatinib monotherapy in the treatment of HCC patients with PVTT 
      and was well tolerated.
CI  - (c) 2023. The Author(s).
FAU - Ji, Xiaoquan
AU  - Ji X
AD  - Department of Radiation Oncology, Senior Department of Oncology, The Fifth 
      Medical Center of PLA General Hospital, Beijing, China.
AD  - The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 
      China.
FAU - Xu, Zhe
AU  - Xu Z
AD  - Treatment and Research Center for Infectious Diseases, The Fifth Medical Center 
      of PLA General Hospital, National Clinical Research Center for Infectious 
      Diseases, Beijing, 100039, China.
FAU - Sun, Jing
AU  - Sun J
AD  - Department of Radiation Oncology, Senior Department of Oncology, The Fifth 
      Medical Center of PLA General Hospital, Beijing, China.
FAU - Li, Wengang
AU  - Li W
AD  - Department of Radiation Oncology, Senior Department of Oncology, The Fifth 
      Medical Center of PLA General Hospital, Beijing, China.
FAU - Duan, Xuezhang
AU  - Duan X
AD  - Department of Radiation Oncology, Senior Department of Oncology, The Fifth 
      Medical Center of PLA General Hospital, Beijing, China. duanxuezhang2006@163.com.
AD  - The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 
      China. duanxuezhang2006@163.com.
FAU - Wang, Quan
AU  - Wang Q
AD  - Department of Radiation Oncology, Senior Department of Oncology, The Fifth 
      Medical Center of PLA General Hospital, Beijing, China. quanwang1987@163.com.
LA  - eng
GR  - 82003211/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20230612
PL  - England
TA  - Radiat Oncol
JT  - Radiation oncology (London, England)
JID - 101265111
RN  - EE083865G2 (lenvatinib)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular
MH  - Retrospective Studies
MH  - *Radiosurgery
MH  - Portal Vein
MH  - *Liver Neoplasms
MH  - *Thrombosis
PMC - PMC10259021
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - Lenvatinib
OT  - Portal vein tumor thrombosis
OT  - Stereotactic body radiotherapy
COIS- The authors declare no competing interests.
EDAT- 2023/06/13 01:14
MHDA- 2023/06/14 06:42
PMCR- 2023/06/12
CRDT- 2023/06/12 23:39
PHST- 2023/01/07 00:00 [received]
PHST- 2023/04/26 00:00 [accepted]
PHST- 2023/06/14 06:42 [medline]
PHST- 2023/06/13 01:14 [pubmed]
PHST- 2023/06/12 23:39 [entrez]
PHST- 2023/06/12 00:00 [pmc-release]
AID - 10.1186/s13014-023-02270-z [pii]
AID - 2270 [pii]
AID - 10.1186/s13014-023-02270-z [doi]
PST - epublish
SO  - Radiat Oncol. 2023 Jun 12;18(1):101. doi: 10.1186/s13014-023-02270-z.